Category Archives: Public Policy

Latest From Public Policy

What International Trade Agreements Have to Do with Innovation

Attendees

Innovation is not just the life-blood of the biotech industry, it is the very premise of the BIO International Convention. So what is a panel on international trade doing here? Answering this question is the task panel moderator, Richard Bergstrom, Director General, EFPIA gave to participants in the session TTIP: Can US and the EU Lead the Way in Setting New Global Benchmarks for IP, Regulatory and Market Access Issues; and each provided a piece Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

BIO Provides Recommendations for Growing India’s Biotech Industry

DNA

BIO and the Association of Biotechnology Led Enterprises (ABLE) released a new report today, entitled Accelerating Growth: Forging India’s Bioeconomy, which present recommendations in support the growth of the country’s Bioeconomy. India’s biotechnology industry is on the cusp of entering a new era when it can provide significant economic growth and development to the people of India and around the world. India already has many of the necessary ingredients needed in order to grow its Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Protecting your IP Overseas

shutterstock_2103563

According to the World Intellectual Property Organization (WIPO), nearly 100,000 biotechnology and pharmaceutical patent applications are filed worldwide each year, and the trend appears to be rising. As you’ve likely experienced, filing patent applications can be very complex, with different laws, deadlines and languages requiring highly technical translators for most countries in which you’re seeking protection. As a result, companies seeking IP protection often outsource their domestic and foreign patent filings to service providers to Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

Patent Parameters

Untitled-1

Supreme Court Finds Naturally Occurring DNA to Be Patent Ineligible Last summer, the Supreme Court issued its decision in Association for Molecular Pathology v. Myriad Genetics, Inc., which concerned the patent eligibility of the BRCA1 and BRCA2 genes. In Myriad, a unanimous Supreme Court held that a naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated. The Court also determined, albeit with one caveat, that Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

US Public Organizations Leading Genomic Research, with Europe and Asia Catching Up

Gareth Williams  - Head Shot (March 2013) C High(2146527_1)

Since before the mapping of the human genome just over a decade ago, we have been applying our growing understanding the genome and associated –omes to medical and industrial uses. Thanks to this understanding, we now have the ability to pinpoint a specific genetic variation in a specific patient which can predict sensitivity to certain drugs. But where is innovation in genomics coming from? And where is it going? What roles are emerging markets playing? Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,